Career

Medical Device Company INVO Bioscience Appoints Meryle Lynn Chamberlain to Lead Marketing for INVOcell, its Infertility Solution

INVO Bioscience, a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell, an effective and affordable treatment for patients diagnosed with infertility, is pleased to announce the appointment of tenured women’s health & fertility solution marketing professional, Meryle Lynn Chamberlain, as Director of Marketing, a newly created position within the company. Chamberlain brings over 15 years of…

Women’s Reproductive Health Pharma Company ObsEva Appoints Clive Bertram as Chief Commercial Officer

ObsEva, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of Clive Bertram as Chief Commercial Officer and member of ObsEva’s Executive Committee, effective May 10, 2021. Wim Souverijns has served as Chief Commercial Officer of ObsEva since November 2018 and will leave the Company on June 30, 2021 to pursue a new opportunity.…

Finance Exec Meredith Whitney Joins Kindbody as the Company’s New CFO

Kindbody today announced Meredith Whitney as its Chief Financial Officer and newest addition to its female-led executive team. Whitney joins Kindbody as a seasoned leader with a long and illustrious career in finance, having shattered the glass ceiling during her time on Wall Street. Whitney has been one of the most visible female analysts on Wall Street, earning recognition from Fortune Magazine as one…

Women’s Health Biotech Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

Daré Bioscience, a leader in women’s health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve…

Bonafide Names Dr. Alyssa Dweck as Chief Medical Officer as the Company Leads the Movement to Provide Hormone-Free Menopause Treatment

Bonafide, the company pioneering mainstream medical use of drug-free, naturally derived health solutions for menopause, announces today that Dr. Alyssa Dweck will join its team as its Chief Medical Officer. Bonafide’s products are already trusted by over 9,000 unpaid health care professionals, primarily OBGYNs, and more than 70,000 women.  The addition of Dr. Dweck to Bonafide’s leadership team is in alignment with…

Dr. Adrienne Day Joins Women’s Health Biotech Celmatix’s Strategic Advisory Board

Women’s health biotech Celmatix focused uniquely on ovarian biology, today announced that Dr. Adrienne Day has joined the company’s advisory board. Dr. Day joins as the company eyes upcoming nonclinical studies for the lead RSTK agonist program, and continued partnering interest in its category-defining multi-omic ovarian health platform. She will play a key role in supporting the strategic and scientific prioritization of…

Gynesonics Appoints Susan Stimson to Its Board of Directors to Provide Key Insights on Global Launch Strategies

Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Susan Stimson has been appointed as an independent member to the company’s Board of Directors. Ms. Stimson joins the Gynesonics’ Board with more than 25 years of experience in the development and commercialization of high-impact medical devices. She currently…

Women’s Health Biotech Celmatix Adds Dr. Stephen Palmer to its Scientific Advisory Board

Celmatix, the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Stephen Palmer has joined its Scientific Advisory Board. Along with other board members, Dr. Palmer will play an instrumental role in supporting the continued success of Celmatix’s lead RSTK agonist program as it progresses through preclinical development, initiation of a follow-on RSTK antagonist program, and continued pipeline…